Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APR-246 with Acalabrutinib or Venetoclax in R/R NHL (CLL/MCL)
NCT04419389Phase 2Terminated
- Sponsor
- Aprea Therapeutics
- Start
- Mar 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eprenetapopt in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Richter's syndrome (RS), sponsored by Aprea Therapeutics. Started Mar 2021; status: terminated.
02
Drugs
eprenetapopt
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT04419389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419389.